Get the Stockscreener App
7.28
2.67%
-0.20
Immunitybio Inc stock is traded at $7.28, with a volume of 14.27M.
It is down -2.67% in the last 24 hours and down -9.11% over the past month.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
See More
Previous Close:
$7.48
Open:
$7.35
24h Volume:
14.27M
Relative Volume:
0.38
Market Cap:
$7.52B
Revenue:
$113.29M
Net Income/Loss:
$-351.47M
P/E Ratio:
-18.68
EPS:
-0.3898
Net Cash Flow:
$-309.19M
1W Performance:
-0.27%
1M Performance:
-9.11%
6M Performance:
+208.47%
1Y Performance:
+195.93%
1-Day Range:
$7.10
$7.55
1-Week Range:
$6.68
$7.64
52-Week Range:
$1.83
$12.43
Immunitybio Inc Stock (IBRX) Company Profile
Name
Immunitybio Inc
Sector
Industry
Phone
(844) 696-5235
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
7.28 | 7.52B | 113.29M | -351.47M | -309.19M | -0.3898 |
VRTX
Vertex Pharmaceuticals Inc
|
436.27 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
748.87 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
799.65 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
322.11 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
309.66 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-26 | Resumed | BTIG Research | Buy |
| May-20-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-06-25 | Initiated | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | BTIG Research | Buy |
| May-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-03-22 | Initiated | Jefferies | Buy |
View All
Immunitybio Inc Stock (IBRX) Latest News
IBRX Investors Eligible to Lead Fraud Lawsuit - National Today
ImmunityBio, Inc. (IBRX) Investors: May 26, 2026, Filing Deadline in Securities Fraud Class ActionContact Kessler Topaz Meltzer & Check, LLP - The Globe and Mail
New ImmunityBio timeline emerges - observertoday.com
Robbins Geller Announces ImmunityBio Investor Lawsuit Deadline - National Today
IBRX SEC FilingsImmunitybio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AQST - GlobeNewswire Inc.
ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before ... - Bluefield Daily Telegraph
ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - GlobeNewswire Inc.
IBRX Stock Rises 7% on Strong Q1 2026 Preliminary Results - TradingView
IBRX INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that ImmunityBio, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - ChartMill
IMMUNITYBIO CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
IBRX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in ImmunityBio, ... - Bluefield Daily Telegraph
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
IBRX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 - PR Newswire
NK Cell Therapy Pipeline 2026: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Amgen, ImmunityBio, Dragonfly Therapeutics, Glycostem Therapeutics, Athenex, Artiva Biotherap - Barchart.com
IBRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ImmunityBio, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Berger Montague PC Investigating Claims on Behalf of ImmunityBio, Inc. (IBRX) Investors After Class Action Filing - marketscreener.com
IBRX Stock Set To Snap 2 Days Of Losses? Anktiva Back In Focus Ahead Of COVID-Cancer Link Data - Stocktwits
ImmunityBio Reports Net Product Revenue Increased Nearly 2.7 Times Year-Over-Year to Record $44 Million in Q1 2026 and $381 Million in Cash and Marketable Securities - BioSpace
IBRX stock in spotlight: ImmunityBio guides for 168% revenue surge in Q1 on ANKTIVA momentum - MSN
ImmunityBio, Inc. (IBRX) Facing Securities Class Action Amid FDA Warning Regarding Unsupported Cancer Treatment Claims, $2 Billion Market Capitalization Wiped Out -- Hagens Berman - PR Newswire
ImmunityBio Reports Record Q1 2026 Revenue - National Today
Why Is ImmunityBio Stock Rallying Thursday? - Benzinga
ImmunityBio, Inc. Reports Preliminary Revenue Results for the First Quarter Ended March 31, 2026 - marketscreener.com
ImmunityBio Stock Climbs 7% as Record $44M Q1 Revenue from ANKTIVA Fuels Biotech Rally - International Business Times Australia
ImmunityBio Shareholder Alert: ClaimsFiler Reminds - GlobeNewswire
ImmunityBio Reports Net Product Revenue Increased Nearly 2.7 Times Year-Over-Year to Record $44 Mill - PharmiWeb.com
Kaplan Fox Encourages Investors of ImmunityBio, Inc. (NASDAQ: IBR - The National Law Review
Kaplan Fox Encourages Investors of ImmunityBio, Inc. (NASDAQ: IBRX) to Contact the Firm Before Lead Plaintiff Deadline on May 26, 2026 - NewMediaWire
ImmunityBio (IBRX): From R&D Speculation to Record Commercial Revenue - The Chronicle-Journal
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming DeadlinesIBRX - PR Newswire
IBRX Stock In Spotlight: ImmunityBio Guides For 168% Revenue Surge In Q1 On ANKTIVA Momentum - Stocktwits
ImmunityBio Secures $100 Million for Global Push Amid Legal and Regulatory Scrutiny - AD HOC NEWS
IMMUNITYBIO, INC. (IBRX) DEADLINE ALERT Bernstein Liebhard - GlobeNewswire
ImmunityBio reports Q1 revenue of $44.2M, up 168% year-over-year - Investing.com
ImmunityBio (NASDAQ: IBRX) Q1 revenue jumps 168% to $44.2M - Stock Titan
IBRX STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ImmunityBio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Kaplan Fox Alerts Investors of ImmunityBio, Inc. (IBRX) to a Securities Class Action Deadline on May 26, 2026 - NewMediaWire
IBRX INVESTOR REMINDER: ImmunityBio, Inc. Investors Have Until May 26, 2026 To Seek Lead Plaintiff Role - Business Wire
Bronstein, Gewirtz & Grossman, LLC Is Investigating ImmunityBio, Inc. (IBRX) And Encourages Shareholders to Connect - ACCESS Newswire
INVESTOR DEADLINE: ImmunityBio, Inc. (IBRX) Investors with - GlobeNewswire
IBRX CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 - marketscreener.com
ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
INVESTOR DEADLINE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action Lawsuit - PR Newswire
IBRX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ImmunityBio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ImmunityBio, Inc. (IBRX) And Encourages Shareholders to Reach Out - ACCESS Newswire
IBRX stock set to snap 2 days of losses? Anktiva back in focus ahead of COVID-cancer link data - MSN
Why is ImmunityBio (IBRX) down 35.8% since last earnings report? - MSN
IBRX Stock In Spotlight As FDA Scrutiny Prompts ImmunityBio To Withdraw Content, Tighten Oversight - Stocktwits
ImmunityBio, Inc. Securities Fraud Class Action Result of - GlobeNewswire
ImmunityBio (IBRX) Stock Falls Following FDA Warning Letter ResponseNews and Statistics - IndexBox
Immunitybio Inc Stock (IBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.95%
3.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):